Skip to main content

Table 1 Basic characteristics at diagnosis of central precocious puberty of the gonadotropin releasing hormone (GnRH) analogue treated and untreated groups

From: Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study

Parameter GnRHa treatment
N = 27
No treatment
N = 24
P value
Age at diagnosis (years) 7.3 ± 0.6 (5.7–8.0) 7.6 ± 0.6 (6.0–8.0) 0.101
Bone age at diagnosis (years) 9.6 ± 1.7 (7.1–12.0) 10.7 ± 1.7 (7.1–13.0) 0.072
Advanced over chronological age (months) 16.4 ± 11.8 (0–43.0) 21.6 ± 12.0 (8.0–50.0) 0.214
Weight at diagnosis (kg) 32.9 ± 8.6 (22.0–58.0) 36.4 ± 11.7 (17.0–67.0) 0.250
Height at diagnosis (centimeters) 130.6 ± 10.4 (114–149) 135.6 ± 14.2 (98–162) 0.189
BMI percentile at diagnosis 80.5 ± 19.3 (15.2–98.9) 75.7 ± 24.9 (1.0–98.4) 0.480
Medical background
 Neurologic 3 (11.1) 5 (20.8) 0.451
 Developmental 2 (8.3) 4 (16.7) 0.402
 Fetal    0.175
  Small for gestational age 1 (3.7) 4 (16.7)  
  Large for gestational age 1 (3.7) 0  
  Prematurity (< 37 weeks) 4 (14.8) 1 (4.2)  
 Endocrine    0.661
  Hypothyroidism 1 (3.7) 0  
  NCCAH 2 (7.4) 2 (8.3)  
  Vitamin D deficiency 0 2 (8.3)  
  Benign premature thelarche 1 (3.7) 1 (4.2)  
Clinical presentation at diagnosis    0.422
 Pubarche and thelarche 19 (70.4) 12 (57.1)  
 Thelarche only 5 (18.5) 5 (23.8)  
 Pubarche only 3 (11.1) 4 (19.1)  
LH at diagnosis (IU/L) 1.9 ± 1.7 (0.1–6.2) 2.1 ± 1.6 (0.3–6.0) 0.722
FSH at diagnosis (IU/L) 3.8 ± 2.3 (1.1–9.4) 4.7 ± 1.9 (1.6–8.3) 0.200
Estradiol at diagnosis (pmol/L) 121.9 ± 56.4 (70–232) 191.2 ± 246.6 (70–1080) 0.296
LH/FSH ratio at diagnosis 0.5 ± 0.3 (0.1–1.0) 0.5 ± 0.4 (0.1–1.4) 0.446
  1. Data presented as Mean ± SD (range) or n (%)
  2. Note: SGA Small for gestational age, LGA Large for gestational age, LH Luteinizing Hormone, FSH Follicle Stimulating Hormone, BMI Body Mass Index, NCCAH Non-classical congenital adrenal hyperplasia